LEUVEN, Belgium and LUND, Sweden, May
17, 2010 /PRNewswire-FirstCall/ —
– Trial to Study Patients with Colorectal and Ovarian Cancer
ThromboGenics NV (Euronext Brussels: THR) and BioInvent
International AB (OMXS: BINV) announce today that their partner
Roche (SIX: RO, ROG; OTCQX: RHHBY) will begin an imaging study with
the novel anti-cancer antibody TB-403 (RG7334) in patients with
metastatic, treatment-refractory, colorectal and ovarian cancers.
ThromboGenics and co-development partner BioInvent will receive a
milestone payment of EUR10 million
from Roche under the terms of the strategic alliance agreement
signed in June 2008. ThromboGenics,
which discovered TB-403, receives 60% and BioInvent 40% of all
revenue from the alliance with Roche for this anti-cancer
antibody.
This trial is a multi-centre, open-label (monotherapy),
dose-finding study with intravenous TB-403. The primary objective
of the study will be to establish the TB-403
concentration-pharmacodynamic (PD) effect relationship using
DCE-MRI (dynamic contrast-enhanced magnetic resonance imaging) and
to identify the minimally PD effective dose. The trial will recruit
up to 50 patients across three European sites.
With the start of this study, Roche will assume responsibility
for all future development of TB-403, continuing the work started
by ThromboGenics and BioInvent. A Joint Steering Committee made up
of representatives from Roche, ThromboGenics and BioInvent will
continue to oversee research and development activities. In
addition, Roche will continue to provide funding to ThromboGenics
and BioInvent for re
‘/>”/>